Plasma cell leukaemia with t(11;14) not responsive to venetoclax

Mohammed Isaac Abu Zaanona, Priyank Patel

Research output: Contribution to journalArticlepeer-review


A 70-year-old man with medical history of IgG kappa multiple myeloma, initially diagnosed in 2017, underwent induction therapy with carfilzomib, lenalidomide and dexamethasone followed by autologous haematopoietic stem cell transplantation. Nine months following transplant, disease relapsed in the form of plasma cell leukaemia. Fluorescent in situ hybridisation of malignant plasma cells revealed t(11;14). A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. Unfortunately, the disease was primary refractory, and after further ineffective therapies, the patient did not have a successful outcome.

Original languageEnglish (US)
Article numbere238641
JournalBMJ Case Reports
Issue number1
StatePublished - Jan 25 2021


  • chemotherapy
  • haematology (incl blood transfusion)
  • oncology

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Plasma cell leukaemia with t(11;14) not responsive to venetoclax'. Together they form a unique fingerprint.

Cite this